ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1662853
Impact of Liver Fibrosis Scores on Short-Term Mortality in ICU Patients with Acute Myocardial Infarction: Evidence from the MIMIC-IV Database and a Chinese Independent Cohort
Provisionally accepted- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Acute myocardial infarction (AMI) has a sudden onset and a high short-term mortality rate. While liver fibrosis scores have shown prognostic value in cardiovascular diseases, their role in predicting short-term outcomes in AMI remains unclear. This study aims to systematically evaluate the predictive role of liver fibrosis scoring systems (FIB-4, APRI, NFS, BARD) in short-term clinical outcomes for patients with AMI. Methods This retrospective cohort study analyzed AMI patients from the Medical Information Mart for Intensive Care IV (MIMIC-IV) and the cardiac intensive care unit (CCU) of First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Primary endpoints were intensive care unit (ICU) and 30-day all-cause mortality. The study used logistic and Cox regression, Kaplan–Meier curves with log-rank tests, restricted cubic spline (RCS), subgroup analyses, and receiver operating characteristic (ROC) curves to assess the associations between liver fibrosis scores and short-term mortality. Results In ICU mortality prediction, area under the curves (AUCs) for FIB-4 were 0.672 (MIMIC) and 0.726 (independent cohort); for APRI, 0.674 and 0.747, respectively; and for NFS, 0.593 and 0.624. Regarding the risk stratification of 30-day mortality, Kaplan–Meier survival curves confirmed the ability of the scores to stratify patients by risk. In both cohorts, the survival curves for groups stratified by FIB-4 were significantly different (log-rank test, P < 0.0001). NFS and APRI also demonstrated a significant ability to differentiate survival outcomes across cohorts (log-rank test, P < 0.05). Multivariate-adjusted logistic regression and Cox regression analyses in both cohorts showed that patients in the highest tertile (T3) of FIB-4, NFS, and APRI scores exhibited a significantly elevated risk of ICU and 30-day all-cause mortality compared with those in the lowest tertile (T1) (all P < 0.05). RCS analyses revealed significant nonlinear associations between FIB-4/APRI and 30-day mortality. Conclusion Elevated liver fibrosis scores (FIB-4, APRI, NFS) are independently associated with increased short-term mortality in patients with AMI. As simple, non-invasive markers, they show promise for the early risk stratification of these high-risk patients and can serve as a useful adjunct for identifying individuals at higher risk.
Keywords: acute myocardial infarction1, Liver Fibrosis Scores2, Short-term Mortality3, Retrospective cohort study4, Risk Prediction5
Received: 09 Jul 2025; Accepted: 22 Aug 2025.
Copyright: © 2025 Wang, Song, Fan and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhiqiang Zhao, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.